Experimental CAR-T therapy targets Hard-to-Treat brain autoimmune diseases

NCT ID NCT07341828

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new treatment called C-CAR168, which uses a patient's own immune cells modified to attack harmful cells in the body. It is for 15 adults with multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person syndrome that have not improved with standard treatments. The main goal is to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
C-CAR168 (a type of CAR-T cell therapy that targets CD20 and BCMA proteins)
What this could lead to
If it works, this could point toward a new treatment option for people with severe central nervous system autoimmune diseases that haven't responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 15 people, focused mainly on safety. It may not show clear benefit, and CAR-T therapy carries risks like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.